



























































9th BIOPRODUCTION CONGRESS

25-26 September 2024 - Tours - France

BIOTHERAPEUTICS DEVELOPABILITY
AND RISK MITIGATION







































































DAY 1

Wednesday, 25 September 2024

09h00	Welcome coffee and registration	
09h50	Welcome address	
10h00	Opening Keynote Lecture - Descartes Auditorium Mastering Keynote: Advancing Biotherapeutic Developability in a Standardized Manufacturing Landscape	
	  <p>Cécile GENY Head of MSAT Global Vaccine Sanofi, France</p>	
10h30	Breakthrough Innovations in Bioproduction - Session I - Descartes Auditorium 10h30 • Exploring Bioproduction : Market Dynamics and Innovations	
	  <p>Anabelle PERRIER Market Research Manager MabDesign, France</p>	
10h40	10h40 • Artificial Intelligence for operational excellence with ROMBIO	
	  <p>Louis DESCHANEL Business Developer Rombio, Belgium</p>	
10h50	10h50 • Process Control as a Pillar for IMPD Approval	
	  <p>Guillaume LAY CCO Cell-Easy, France</p>	
11h00	11h00 • CellSecret•Service Platform Transforms Secretomes from Resolution-Associated Macrophages into Biological Drugs	
	  <p>Sylvain PERRUCHE CEO MED'INN'Pharma, France</p>	
11h15	Round Table I - Due Diligence in Bioproduction: Legal and Financial Perspectives for Successful Transactions - Descartes Auditorium	
	  <p>Michael SNEIJERS Director Archimed, France</p>	
	  <p>Charles CORNEVIN Principal Lauxera Capital Partners, France</p>	
	  <p>Alexandre BOULAY Investment Director GoCapital, France</p>	
	  <p>Loïc LEMERCIER Partner Dentons, France</p>	
12h00	Lunch at the Exhibition Hall	
14h00	Parallel Workshops Accelerate biotech process development	
	 <p>Business continuity plan : Don't forget to secure the storage of your biological resources!</p>  <p>Point-of-need analytics and process analytical technologies: 4 case studies</p>  <p>Journey to Immerscio.bio new trainings through Virtual Reality, Serious Game and Video Workshops</p> 	
15h30	Break	
15h40	Biologics Developability - Session I - Descartes Auditorium 15h40 • Antibodies and ADCs: Developability Risks Mitigation	
	  <p>Alain BECK Senior Director, Biologics CMC and Developability Laboratoires Pierre Fabre, France</p>	Analytical Methods - Pasteur Auditorium 15h40 • How to accelerate vaccine process development by digitalization and automation: definition of an optimized Workflow for Bioprocess and Analytic Laboratories
	  <p>Paul WASSMANN Senior Principal Scientist Novartis, Switzerland</p>	  <p>Stéphanie RICHARD Head of Vaccines Development Unit Manager Sanofi, France</p>
16h20	16h20 • A library approach for the de novo high-throughput isolation of humanized VHH domains with favorable developability properties following camelid immunization	
	  <p>Stefan ZIELONKA Global Head of Antibody Discovery & Protein Engineering Merck Healthcare KGaA, Germany</p>	  <p>Loïc BENAIR Senior Scientist Drug Substance Development Sanofi, France</p>
16h40	16h40 • VMF: Disruptive & sustainable Vibrio® technology for improving bioprocesses yield and environmental footprint	
	  <p>Jarno ROBIN Pharma Business Development Director SANI Membranes, Denmark</p>	  <p>Antonio ROLDAO Head of Vaccines Development Lab iBET, Portugal</p>
16h50	16h50 • Cell sampling ? A critical step to master your upstream bioprocess (USP) monitoring	
	  <p>Joelle EID Field Application Scientist GenSensor, France</p>	  <p>Delphine GRICOURT Marketing Director PathoQuest, France</p>
	  <p>Pauline SOUETRE Quality Control Manager Etablissement Français du Sang (EFS), France</p>	  <p>Pauleine SOUETRE Quality Control Manager Etablissement Français du Sang (EFS), France</p>
	  <p>Arnaud DELOBEL R&D and Innovation Director Quality Assistance, Belgium</p>	  <p>Arnaud DELOBEL R&D and Innovation Director Quality Assistance, Belgium</p>
	  <p>Bérengère FRANÇOIS EU Biomanufacturing Team Lead Repligen, Europe</p>	  <p>Bérengère FRANÇOIS EU Biomanufacturing Team Lead Repligen, Europe</p>
	  <p>Alan DEDUYER DSP Scientist Drug Substance Development Sanofi, France</p>	  <p>Alan DEDUYER DSP Scientist Drug Substance Development Sanofi, France</p>

DAY 2

Thursday, 26 September 2024

08h00	Welcome Coffee	
08h30	Sustainable Manufacturing - Descartes Auditorium 08h30 • Leveraging data to foster value chain collaboration and enabling the industrial Sustainability transformation.	
	  <p>Thibault RENAUD Global Sustainability Supply Chain Leader Cytiva, France</p>	Quality & Regulatory - Pasteur Auditorium 08h30 • Specific CMC regulatory requirements to fill FIH in China, Taiwan and South Korea for a biological product
	  <p>Caroline CALMELS Sustainability Market Manager Saint-Gobain Life Science, France</p>	  <p>Carole LASSERRE Regulatory Affairs Leader, CMC Pre-MA Expert Laboratoires Pierre Fabre, France</p>
09h10	09h10 • How to reach Sustainable Biomanufacturing using Virtual Twins powered by real-world data	
	  <p>Clément GLACE Life Sciences Manufacturing Solution Leader Dassault Systèmes, France</p>	  <p>Hervé BROLY ex-VP Biotech Process Development Merck Serono, Switzerland</p>
09h30	09h30 • OneCellab™ - Unleashing Full data potential and next-gen digital twins for more sustainable R&D and manufacturing	
	  <p>Adama OUATTARA CEO and co-founder Gencovey, France</p>	  <p>Yucal LI Vice President of CMC Management, leading WuXi Biologics European CMC team WuXi Biologic, Sweden</p>
09h40	Round Table II - Empowering Industrial Sustainable Transformation through Collaborative & Digital Solutions - Descartes Auditorium	
	 	 
	 	
10h10	Coffee Break at the Exhibition Hall	
11h00	Round Table IV - Training 4.0: Impact of e-Learning and Artificial Intelligence - Pasteur Auditorium	
	    	
12h20	Lunch at the Exhibition Hall	
14h00	Breakthrough Innovations in Bioproduction - Session II - Descartes Auditorium 14h00 • Molecular optical spectroscopy as a PAT tool in USP bioprocessing	
	  <p>Igor CHOURPA Professor, Director of EA 6295 Nanomedicines and Nanoprobes, Director of the Analytical Chemistry Laboratory University of Tours, France</p>	  <p>Hirovuki KANDA Global Product Leader Rigaku Corporation, Japan</p>
14h30	14h30 • iGEM: Sparking Innovation Pipeline from Training to Startup	
	  <p>Dorothy ZHANG Vice President of Global Development iGEM, France</p>	  <p>Yucal LI Vice President of CMC Management, leading WuXi Biologics European CMC team WuXi Biologic, Sweden</p>
14h50	Advancements and Perspectives in Bioproduction: Insights from Leading Experts of the Field - Descartes Auditorium 14h50 • The Biotherapeutics and Bioproduction of Innovative Therapies Research Program (PEPR): How can we support the academic community?	
	  <p>Fanny CAPUTO Comité de pilotage du PEPR Biothérapies CEA Paris-Saclay, France</p>	  <p>Philippe GRIMM Business Development & Marketing Director SGS Vitrology, Scotland</p>
15h00	15h00 • CIG ASP Biotherapy Processes - Update on Technical Guide: How to optimize the development and industrialization of your Biotherapy Product	
	  <p>Marie CECILLE Head of CMC Leaders Merck Life Science, France</p>	  <p>Yucal LI Vice President of CMC Management, leading WuXi Biologics European CMC team WuXi Biologic, Sweden</p>
	  <p>Géry VAN VYNCHT Scientific Director Quality Assistance, Belgium</p>	  <p>Géry VAN VYNCHT Scientific Director Quality Assistance, Belgium</p>
15h30	15h30 • How to select your CDMO? Insights from France Biotech's biomanufacturing committee	
	  <p>Jérôme GABARD Founder & CEO BioMaje, France</p>	  <p>Jérôme GABARD Founder & CEO BioMaje, France</p>
	  <p>Frédéric DESDOITS CEO TreeFrog Therapeutics, France</p>	  <p>Frédéric DESDOITS CEO TreeFrog Therapeutics, France</p>
	  <p>Marc-Olivier MIGNON Chief Commercial Officer CELLFORCURE by Seqens, France</p>	  <p>Marc-Olivier MIGNON Chief Commercial Officer CELLFORCURE by Seqens, France</p>
	  <p>Alain SAINOT CEO GTP Bioways, France</p>	  <p>Alain SAINOT CEO GTP Bioways, France</p>
16h10	Closing Keynote Lecture - Descartes Auditorium 16h10 • The Drug Cell - Projet Important d'Intérêt Européen Commun (PIIEC), Med4Cure	
	  <p>Frédéric DEHAUT National Director of Biology, Therapeutics and Diagnostics Etablissement Français du Sang (EFS), France</p>	  <p>Yucal LI Vice President of CMC Management, leading WuXi Biologics European CMC team WuXi Biologic, Sweden</p>
	  <p>Hervé DE MALLIARD Chairman MGA Technologies, France</p>	  <p>Hervé DE MALLIARD Chairman MGA Technologies, France</p>
16h40	Closing remarks	
17h00	End of the BIOPC2024 Congress	